Halberd Corporation Adds Edson Brito to Scientific Advisory Board
Halberd Corp. (OTC PINK: HALB) announced the appointment of Edson Brito to its Scientific Advisory Board. With extensive experience in sales and business development in the pharma sector, Brito aims to facilitate the advancement of COVID-19 treatments in international markets. Chairman William Hartman expressed confidence in Brito's expertise, particularly regarding the company's research and development efforts. Halberd holds exclusive rights to multiple provisional patents for COVID-19 treatment, emphasizing its commitment to addressing the pandemic.
- Appointment of Edson Brito enhances expertise in sales and business development for COVID-19 treatments.
- Brito's background may accelerate Halberd's entry into international markets.
- Ongoing funding issues previously noted may impact development timelines.
- Uncertainty regarding the COVID-19 pandemic's impact on operations and financial performance.
JACKSON CENTER, PA / ACCESSWIRE / August 12, 2020 / Halberd Corp. (OTC PINK:HALB) today announced the addition of Edson Brito to the Scientific Advisory Board. Mr. Brito is CEO and Chief Business Development Officer of Cellybri Advanced Therapies in Brazil.
Mr. Brito graduated with a Chemistry degree from Faculdade São Bernardo and went on to study Pharmacology and Biochemistry at the Universidade Bandeirante de São Paulo, Brazil. He is a registered member of the Conselho Regional de Farmacia de São Paulo. Mr. Brito obtained a Master's degree in International Business Management and Marketing from the Instituto Paulista de Ensino e Pesquisa (IPEP) in São Paulo.
Mr. Brito has held various positions in sales and business development for a number of prominent pharma and biochemical companies in Brazil, and currently holds the position of Chief Business Development Officer and CEO of Cellybri Advanced Therapies in Brazil. Prior to his current position, Mr. Brito was Executive Consultant for Central and South America for the Korea Health Industry Development Institute - KHIDI of Seoul, South Korea. Prior to that, he held the position of Director of Business Development for Auramedi Farmaceutica, in Brazil.
William A. Hartman, Chairman, President & CEO of Halberd Corporation, stated, "Mr. Britio brings a wealth of experience in Sales, Marketing and Business Development to Halberd Corporation, especially in the South American region. We hope his knowledge and skills will help us to quickly bring Covid-19 treatments to International Markets after receiving regulatory approvals."
Hartman continued, "Now that we have temporarily resolved issues regarding funding and team building, our current focus is on working with a shortened list of potential university partners to complete our R&D program to develop specific antibodies in select moieties and the optimum associated extraction process. We are making significant progress and should be able to release a status report shortly."
For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com
support@halberdcorporation.com
www.halberdcorporation.com
P. O. Box 25
Jackson Center, PA 16133
Twitter:@HalberdC
About Halberd Corporation.
HalberdCorporation. (OTC PINK:HALB), is a publicly-traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. It is debt-free and holds the exclusive rights to the COVID-19 extracorporeal treatment technology provisional patent applications: "Method for Treating and Curing Covid-19 Infection;" "Method for Treating COVID-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in COVID-19 Patients;" and "Method for Treating and Curing COVID-19 Infection by Utilizing a Laser to Eradicate the Virus." Halberd also holds the exclusive rights to the underlying granted U.S. Patent 9,216,386 and U.S. Patent 8,758,287.
Title | Application No. | Filing Date | Priority | Status |
Method for Treating and Curing Covid-19 Infection | US 62/989981 | 03/16/2020 | n/a | Provisional application Pending |
Method for Treating Covid-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in Covid-19 Patients | US 63/007207 | 04/08/2020 | n/a | Provisional application Pending |
Method for Treating and Curing Covid-19 Infection by Utilizing a Laser to Eradicate the Virus | US 63/013104 | 4/21/2020 | n/a | Provisional application Pending |
Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). The Companies caution that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. The Companies undertake no obligation to revise these statements following the date of this news release.
Investor caution/added risk for investors in companies claiming involvement in COVID-19 initiatives -
On April 8, 2020, SEC Chairman Jay Clayton and William Hinman, the Director of the Division of Corporation Finance, issued a joint public statement on the importance of disclosure during the COVID-19 crisis.
The SEC and Self-Regulatory Organizations are targeting public companies that claim to have products, treatment or other strategies with regard to COVID-19.
The ultimate impact of the COVID-19 pandemic on the Company's operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak. Additionally, new information may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced customer traffic and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time.
We further caution investors that our primary focus and goal is to battle this pandemic for the good of the world. As such, it is possible that we may find it necessary to make disclosures which are consistent with that goal, but which may be adverse to the pecuniary interests of the Company and of its shareholders.
SOURCE: Halberd Corporation
View source version on accesswire.com:
https://www.accesswire.com/601274/Halberd-Corporation-Adds-Edson-Brito-to-Scientific-Advisory-Board
FAQ
Who is Edson Brito in relation to Halberd Corp.?
What is the significance of Edson Brito's appointment for HALB?
What are Halberd Corp's COVID-19 treatment patents?
How might the COVID-19 pandemic affect Halberd Corp's operations?
